Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New combo therapy aims to stop aggressive liver Cancer's return

NCT ID NCT07337460

Summary

This study is testing whether a combination of a traditional Chinese medicine capsule (Icaritin) and a specialized form of chemotherapy delivered directly to the liver can help prevent liver cancer from returning after surgery. It is for patients who have had their tumor surgically removed but are at high risk of the cancer coming back. The goal is to see if this approach can extend the time patients remain cancer-free and improve their survival.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Clinical Medical College of Yangzhou University

    RECRUITING

    Yangzhou, Jiangsu, 225001, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.